Variations in Hypnotic Use and Cardiovascular Risk in Insomnia Patients
Overview
A large prospective cohort study of 124,445 insomnia patients revealed heterogeneous cardiovascular risks associated with different hypnotic categories. Benzodiazepine use was linked to increased cardiovascular events, particularly heart failure, while Z-drugs showed no significant cardiovascular risk increase.
Background
Insomnia is a prevalent sleep disorder associated with increased cardiovascular morbidity and mortality. Treatment options include cognitive-behavioural therapy and pharmacological agents, primarily benzodiazepines and Z-drugs. Previous studies on hypnotics and cardiovascular risk have been inconsistent, with some suggesting increased risk and others showing no significant association. Understanding the cardiovascular safety profiles of hypnotics is crucial for optimizing insomnia management.
Data Highlights
Hypnotic Category
Cardiovascular Risk
Specific Findings
Benzodiazepines
Increased risk
Small but significant increase in heart failure risk; safety concerns for coronary heart disease, stroke, and cardiovascular death
Z-drugs
No increased risk
No significant increase in cardiovascular events; slight increase in heart failure risk observed in cohort
Subgroup Analysis
Sex differences
Females more susceptible to adverse cardiovascular effects than males
Key Findings
Use of benzodiazepines in insomnia patients is associated with a small but statistically significant increase in heart failure risk and other cardiovascular events.
Z-drugs do not significantly increase the risk of cardiovascular events in insomnia patients.
Females appear more vulnerable to the adverse cardiovascular effects of benzodiazepines than males.
The study combined observational data with Mendelian randomization to strengthen causal inference.
Limitations include lack of data on hypnotic dosage, duration, and severity of insomnia, as well as limited ethnic diversity.
Cognitive-behavioural therapy remains the first-line recommended treatment for insomnia due to its efficacy and potential cardiovascular benefits.
Clinical Implications
Clinicians should exercise caution when prescribing benzodiazepines for insomnia, particularly in female patients, due to potential cardiovascular risks. Z-drugs may be a safer pharmacological alternative regarding cardiovascular outcomes. Emphasis on cognitive-behavioural therapy as first-line treatment is warranted to minimize pharmacological risks.
Conclusion
This large-scale study highlights differential cardiovascular risks associated with hypnotic categories in insomnia patients, underscoring the need for cautious use of benzodiazepines and prioritization of non-pharmacological therapies. Further interventional studies are needed to confirm these findings and guide clinical practice.
